Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. Co.'s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Co. is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. We show 13 historical shares outstanding datapoints in our coverage of TRDA's shares outstanding history.
Understanding the changing numbers of TRDA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TRDA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TRDA by allowing them to research TRDA shares outstanding history
as well as any other stock in our coverage universe. |
Free TRDA Email Alerts:
Video: Shares Outstanding Importance
